Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 8/20 | 0.60 |
| ▸ | KDR | P35968 | 10/20 | 0.58 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3032375 | 0.89 | KDR (0.73) | FLT3KDRGABRG2GABRB3GABRA3 | |
| SCHEMBL3032412 | 0.87 | FLT3 (0.59) | FLT3KDRFGFR3GABRG2GABRB3 | |
| SCHEMBL3032518 | 0.87 | FLT3 (0.62) | FLT3KDRFGFR3GABRG2GABRB3 | |
| SCHEMBL3026485 | 0.87 | FLT3 (0.62) | FLT3KDRFGFR3GABRG2GABRB3 | |
| SCHEMBL3034003 | 0.85 | KDR (0.80) | FLT3KDRFGFR3GABRG2GABRB3 | |
| SCHEMBL3021755 | 0.85 | KDR (0.60) | FLT3KDRFGFR3GABRG2GABRB3 | |
| SCHEMBL3033044 | 0.85 | FLT3 (0.51) | FLT3KDRFGFR3 | |
| SCHEMBL3033391 | 0.83 | KDR (0.61) | FLT3KDRFGFR3GABRG2GABRB3 | |
| SCHEMBL3031386 | 0.83 | KDR (0.64) | FLT3KDRFGFR3GABRG2GABRB3 | |
| SCHEMBL3029030 | 0.83 | KDR (0.74) | FLT3KDRFGFR3GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367662-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-02-05 | — | — | US | disclosed |
| EP-2212323-B1 | IMIDAZO [1,2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | NOVARTIS AG (CH) | 2012-08-15 | — | — | EP | disclosed |
| US-20100210641-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-08-19 | — | — | US | disclosed |
| EP-2212323-A2 | IMIDAZO [1,2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009050183-A2 | IMIDAZO [1, 2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210641-A1 | Organic Compounds | ALK, ACVR1, ACVRL1 | FLT3 4384/4885KDR 372/4885FGFR3 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.